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Abstract. Thenovel severe acute respiratory syndrome-coronavirus-2 pandemichasspread toAfrica,wherenearly all
countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are on-
going clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scien-
tifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the
commonly usedantimalarials chloroquine (CQ) andhydroxychloroquine (HCQ)havebecome the focusof global scientific,
media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been
usedworldwide for about 75 years and is listed by theWHOasan essentialmedicine to treatmalaria. Hydroxychloroquine
is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of
COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive
shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to
substandard and falsified medical products, and safety issues are especially concerning for Africa because of its
healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated pro-
duction, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug;
this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider
implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial
during this pandemic.
PERSPECTIVE
Novel coronavirus disease (COVID-19), caused by the novel
severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2), has rapidly spread into a global pandemic. Africa
initially appeared spared, but as of this writing, all countries
except Lesotho have confirmed cases. As of April 15, 2020, there
were 11,367 confirmed COVID-19 cases, with 523 deaths
(4.6% case fatality) reported across the WHO African region.1
In other settings suchas theUnitedStates, Europe, andChina,
morbidity and mortality have been highest in those older than
60 years and with underlying comorbidities such as arterial
hypertension, heart disease, diabetes, and chronic lung dis-
ease; young adults and children seem to have relatively mild
disease and low mortality.2,3
To date, there are no proven, clinically effective pharma-
cological treatments against COVID-19, but multiple ongoing
trials are evaluating novel and repurposed drugs.4 Among the
repurposed drugs being rapidly investigated are the com-
monly used antimalarial and anti-inflammatory drugs chloro-
quine (CQ) and hydroxychloroquine (HCQ).5 Thesedrugs have
become the focus of global scientific, media, and political
attention despite the lack of randomized controlled trials
supporting their efficacy against COVID-19.6 Chloroquine has
been used worldwide for about 75 years, and it is listed by the
WHO as an essential medicine for malaria, whereas HCQ is
widely used to treat autoimmune diseases such as systemic
lupus erythematosus (SLE) and rheumatoid arthritis (RA).7
Both drugs have an established clinical safety profile,8 but
their efficacy and safety for COVID-19 treatment or prevention
remain to be defined.9,10
Chloroquine is a 4-aminoquinoline that was synthesized in
Germany by Bayer in 1934 and emerged in the 1940s as an
effective substitute for quinine, an antimalarial therapy used
for centuries.11 Once a frontline drug for the treatment and
prophylaxis of malaria, the efficacy of CQ was mostly lost
because of the emergence of CQ-resistant Plasmodium fal-
ciparum strains in all endemic regions, including sub-Saharan
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Africa. Since about 2005, CQ has been replaced by artemisinin-
based combination therapy to treat uncomplicated P. falciparum
malaria across Africa, but it is still widely used to treat non-
falciparummalaria, primarily outside of Africa.12 After CQ was
found to have persistent immunomodulatory effects after
cessation of short-term treatment, Winthrop developed and
patented HCQ, which has an N-hydroxyl-ethyl side chain in
place of the N-diethyl group, and therefore less tissue accu-
mulation and a more favorable safety profile than CQ.13,14
There are rational arguments, preclinical evidence of ac-
tivity, and long-term evidence of safety for other indications to
justify CQ/HCQ trials for the treatment and prevention of
COVID-19.15 Their mechanisms of action are incompletely
understoodbutmay include fusion and uncoating blockade,17
lysosomal alkalinization,18 interaction with the angiotensin-2
converting enzyme receptor,19 and immune modulation.20
However, in vitro antiviral activity of CQ/HCQhas not yet been
translated into efficacy for any viral infection, and these drugs
have been detrimental in some studies (e.g., for the treatment
of chikungunya).16 Of note, for SARS-CoV-2, the in vitro ac-
tivity of HCQ appears to be greater than that of CQ, which
might allow for a lower dosage for HCQ.21,22 To date, the
quality of available evidence for the clinical effectiveness of
CQ/HCQ alone or in combination with other drugs (e.g., azi-
thromycin) is low, because of small sample size, poorly de-
fined clinical outcomes, and lack of randomization in published
studies.23–26Thus, the results ofearlyclinical studies cannot yet
be considered conclusive.
There remains an urgent need for high-quality evidence on
the clinical value of CQ/HCQ alone or in combination with
other drugs for the treatment of COVID-19. One global-scale
effort is the ongoing WHO Solidarity trial, a large, adaptive,
five-arm multinational (including South Africa) trial com-
paring four potential COVID-19 regimens: remdesivir, HCQ,
lopinavir–ritonavir, and lopinavir–ritonavir plus interferon beta,
all of which are compared with optimal supportive care, with
in-hospital mortality as the primary end point. Secondary end
points will be the duration of hospital stay and proportion of
patients requiring intensive care unit admission or mechanical
ventilation. The adaptive study design allows for dropping
poorly performing arms and including additional promising
therapeutics.27 Discovery is a component of the Solidarity
trial, with identical arms and more complex end points, and is
funded by the “Institut National de la Santé et de la Recherche
Médicale,” France’s national health and medical research
agency. More than 500 patients have already been enrolled in
the Discovery trial, and preliminary analysis is ongoing. Also,
the Recovery trial (for randomized evaluation) is a UK com-
ponent of Solidarity, withmore than 1,500 participants already
enrolled.27 Also, CQ/HCQ Prevention of COVID-19 in the
Healthcare Setting (COPCOV), a large (n = 40,000) multi-
centric trial in which participants will be randomized to re-
ceive either CQ or HCQ versus placebo, is being launched in
Europe and Asia, and participation of African sites is being
considered.28
Unfortunately, indiscriminate promotion of CQ/HCQ (with or
without azithromycin) basedon the aforementioned low-quality
data for COVID-19 treatment has led to widespread shortages,
self-use, and fatal overdoses.29 Chloroquine (and to a lesser
extent HCQ) has been used for decades with few major safety
issues at the usual antimalarial dosages in short-course regi-
mens (2.5g in3days for³60kgadults).30Although rare, cardiac
toxicity (corrected QT interval [QTc] prolongation leading to
torsades de pointes and ventricular fibrillation) is a serious, life-
threatening complication, especially in patients with underlying
cardiac disease, concurrent use of other drugswith QTc effect,
or with supratherapeutic dosing.26 The therapeutic window is
however larger with HCQ, which is mainly used in chronic ad-
ministration for rheumatic disorders, usually at dosages of 200
to 400mg/day in adults. Themajor toxicity of chronic CQ/HCQ
use is retinopathy.31 Other important adverse effects associ-
ated with CQ/HCQ are listed in Table 1.31–36 Of great concern
are frequent drug–drug interactions between CQ/HCQ and
othermedicationsused for prevalent chronic diseases inAfrica,
such as HIV infection and tuberculosis, and the concurrent
use of antibiotics such as fluoroquinolones (Table 2).37–44 As an
example, coadministration of azithromycinwithCQ/HCQshould
be cautiously approached and closely monitored because of
additive risk for QTc prolongation and subsequent cardiac
complications.32
Of note, P. falciparum resistance to CQ is widespread in
sub-Saharan Africa, and artemisinin-based combination
therapy has been the first-line treatment for uncomplicated
malaria in all African countries for more than 10 years.11 Al-
though currently inappropriate, widespread CQ/HCQ use for
COVID-19 treatment or prevention should therefore have little
impact on P. falciparum treatment outcomes. However, this
may increase selection of resistance to CQ in P. falciparum,
which has decreased in recent years, or in other Plasmodium
species, for which CQ remains the treatment of choice.45
Furthermore, we call for caution regarding thewidespread use
of azithromycin (coadministered with CQ/HCQ) for treatment
of COVID-19, as it may increase selection of bacterial re-
sistance to this macrolide. In sub-Saharan Africa, azithromycin
is an important treatment for bacterial infections including ty-
phoid fever, especially where multidrug resistance (ampicillin,
chloramphenicol, trimethoprim–sulfamethoxazole, and fluo-
rquinolones) in Salmonella typhi is on the rise.46,47
Other concerns regarding the promotion of untested ther-
apies for COVID-19 include fraud related to the growing
TABLE 1
Main side effects of Chloroquine and Hydroxychloroquine31–36
System Chloroquine Hydroxychloroquine
Cardiovascular QTc prolongation and cardiomyopathy QTc prolongation and cardiomyopathy
Gastrointestinal Nausea, vomiting, and abdominal pain Nausea, vomiting, and abdominal pain
Dermatologic Pruritis Pruritis
Musculoskeletal Myopathies and myasthenia-like syndromes Sensorimotor disorders
Nervous Seizures, tinnitus, and dystonia Headache, dizziness, and tinnitus
Psychiatric Depression and psychosis Emotional lability
Ocular Maculopathy and macular degeneration, and retinopathy Blurred vision and retinopathy
Metabolic Hypokalemia, hypercalcemia, and hypoglycemia Hypoglycemia
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market of substandard and falsified drugs48 and diversion of
CQ/HCQ from other chronic conditions for which they are
medically indicated, in particular SLE and RA.49 Safety issues
are especially concerning for Africa because of relatively weak
monitoring systems for off-label drug use and adverse events;
these systems are robust in countries with strong national
insurance schemes or with adequate private sector medical
insurance. In addition, the promotion of CQ/HCQ for COVID-
19 may lead to shortages and/or increased market prices of
these medicines for malaria, SLE, and RA. One strategy to
protect African countries from these threats is to leverage a
collaborative network like the African Vaccine Regulatory
Forum to coordinate cross-continental production, distribu-
tion chains, and post-marketing surveillance. Another model
for quick, low-cost distribution of a COVID-19 drug or vaccine
(once proven efficacious) would be to piggyback on platforms
currently supported by the Global Fund, the U.S. President’s
Emergency Plan for AIDS Relief, and other organizations.
African countries should also establish and strengthen
prescription-monitoring schemes to ensure that off-label use of
any drug(s) is appropriate and beneficial in this pandemic. For
example, in South Africa, prescribers are required to inform the
regulatory agency about off-label use of existing drugs in
COVID-19 treatment. This process will help gather information
on treatment outcomes pending results from clinical trials.
Importantly, patients at risk of COVID-19 complications are
also those most at risk of drug–drug interactions and drug-
associated toxicity. These include the following patients: 1)
older than 60 years (estimated at 10–20% of the African pop-
ulation)50; 2) with comorbidities, such as arterial hypertension
(30% of African adults),51 diabetes (4% of African adults),52
chronic lung disease, malignancies, and immunosuppressive
conditions; and 3) concurrently receiving medications with
potential for drug interactions or additive toxicity. For these
vulnerable populations, off-label CQ/HCQ use should be con-
sidered with the utmost care, ideally following monitored re-
search protocols in hospital and outpatient settings.
In conclusion, there is currently no evidence that CQ or
HCQ, two low-cost drugs for which we have extensive expe-
rience for treatment of malaria and rheumatic disorders, has
beneficial effects on the clinical course of COVID-19 patients.
There are more than 80 ongoing trials of CQ or HCQ, used
alone or in combinationwith a variety of other drugs registered
on ClinicalTrials.gov. The results of these studies, including
Solidarity and its companion trials (Discovery and Recovery)
as well as COPCOV are eagerly awaited. Meanwhile, the off-
label useofCQandHCQ toprevent or treatCOVID-19 inAfrica
and elsewhere must be viewed with greatest caution, con-
sidering potential serious toxicities and benefit versus risk. If
the effectiveness of these and other drugs is established in
global trials, therapeutics for COVID-19 will require further
operational evaluation in Africa.
Received April 14, 2020. Accepted for publication April 16, 2020.
Published online April 22, 2020.
Acknowledgments: We thank David Sullivan and Clive Schiff, Johns
Hopkins Bloomberg School of Public Health, Baltimore, MD, for their
critical reading of our manuscript. Publication charges for this article
were waived due to the ongoing pandemic of COVID-19.
Disclosure: Nachega is an infectious disease internist and epidemi-
ologist supported by U.S. National Institutes of Health (NIH)/National
Institutes of Allergy and Infectious Diseases (NIAID) grant number
5U01AI069521 (Stellenbosch University Clinical Trial Unit (CTU) of
AIDS Clinical Trial Group [ACTG]) as well as NIH/Fogarty International
Center (FIC) grant numbers 1R25TW011217-01 (African Association
forHealthProfessionsEducationandResearch) and1D43TW010937-
01A1 (the University of Pittsburgh HIV-Comorbidities Research
Training Program in South Africa). He serves on the scientific program
committee of the American Society of Tropical Medicine and Hygiene
(ASTMH) and is a senior fellow alumni of the European Developing
Countries Clinical Trial Partnership (EDCTP). Muyembe-Tamfum has
been on the front lines of Ebola research since 1970s, identifying
nosocomial and burial transmission as two of the major causes of
disease transmission, contributing to vaccine research, developing
antisera therapy, and training a new generation of disease responders
and Congolese laboratory. He is now leading the COVID-19 Task
ForceResponse in theDemocraticRepublic of theCongo.Sir Zumla is
a co-PI of the Pan-African Network on Emerging and Re-Emerging
Infections (PANDORA-ID-NET—https://www.pandora-id.net/) fun-
ded by the EDCTP, the EU Horizon 2020 Framework Program for
Researchand Innovation. Sir Zumla is in receipt of aNational Institutes
of Health Research senior investigator award. Seydi is an infectious
diseases and tropical medicine expert and member of the COVID-19
Task Force Response in Senegal. Suleman is a Public Health Phar-
macist supported by a NIH/Fogarty International Center (FIC) grant
number 1R25TW011217-01 (African Association for Health Profes-
sions Education and Research). Dr. Sam-Agudu is a Pediatric In-
fectious Diseases clinician-scientist supported by the NIH/National
Institute of Child Health and Human Development (NICHD) grant
R01HD089866, and by an NIH/FIC award under the Adolescent HIV
Prevention and Treatment Implementation Science Alliance (AHISA),
for the Central and West Africa Implementation Science Alliance
(CAWISA). Prisca Olabisi Adejumo is a professor of Medical Surgical
Nursing, a nurse educator supported by NIH/Fogarty International
Center (FIC) grant number1R25TW011217-01 (AfricanAssociation for
Health Professions Education and Research). All authors have an in-
terest in emerging and reemergingpathogens anddeclare no conflicts
of interest.
Authors’ addresses: Pascale M. Abena, Infectious Diseases Out-
patient Clinic, Douala, Cameroon, E-mail: abenamessomo@yahoo.fr.
TABLE 2
Drug interactions between CQ/HCQ and antituberculous or antiretroviral therapies
Medicine Potential interaction with CQ/HCQ
Efavirenz Limited clinical data. May increase (inhibition of CYP2C8) or decrease
(induction of CYP3A4) exposure. Concurrent usemay increase the risk
of QT interval prolongation.
Lopinavir/ritonavir or atazanavir/ritonavir Limited clinical data. May increase exposure by inhibition of CYPs 2C8,
3A4, and 2D6. Concurrent use may increase the risk of QTc interval
prolongation.
Rifampicin Limited clinical data. Induces phase-I and phase-II enzymes and
transporters. Induction of CYP3A4 may decrease CQ/HCQ exposure.
Levofloxacin and moxifloxacin Concurrent use may increase the risk of QTc interval prolongation.
Bedaquiline Concurrent use may increase the risk of QTc interval prolongation.
CQ = chloroquine; HCQ = hydroxychloroquine. The metabolism of HCQ and CQ is predominantly mediated by the hepatic cytochrome P450 (CYP) enzymes 3A4 and 2D6, but 2C8 and 3A5 are
also important. Any drug that induces or inhibits these CYP enzymes may potentially alter CQ/HCQ concentrations.37–44
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Abidjan, Côte d’Ivoire, E-mail: sergeholie@yahoo.fr. Edward J. Mills,
School of Public Health, University of Kigali, Kigali, Rwanda, E-mail:
emills@mteksciences.com. Oscar Kallay, Department of Ophthal-
mology,ErasmusUniversityClinics,Brussels,Belgium,E-mail: oscar_
kallay@yahoo.fr. Alimuddin ZumlaFRCP, Department of Infection,
Division of Infection and Immunity, Centre for Clinical Microbiology,
University College London, London, United Kingdom, and National
Institute for Health Research Biomedical Research Centre, University
College London Hospitals, London, United Kingdom, E-mail:
a.zumla@ucl.ac.uk. Jean B Nachega, Center for Infectious Diseases,
at Stellenbosch University, Cape Town, South Africa, Department of
International Health and Epidemiology, Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, and University of Pittsburgh
Graduate School of Public Health and Center for Global Health,
Pittsburgh, PA, E-mail: jbn16@pitt.edu.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits un-
restricted use, distribution, and reproduction in anymedium, provided
the original author and source are credited.
REFERENCES
1. World Health Organization, 2020. Coronavirus Disease 2019
(COVID-19) Situation Report – 86. Available at: https://www.
who.int/emergencies/diseases/novel-coronavirus-2019/
situation-reports. Accessed April 16, 2020.
2. Kolifarhood K, Aghaali M, Saadati HM, Taherpour N, Rahimi S,
Izadi N, Nazari SSH, 2020. Epidemiological and clinical aspects
ofCOVID-19; anNarrative review.ArchAcadEmergMed8:e41.
3. Zhou F et al., 2020. Clinical course and risk factors for mortality of
adult inpatients with COVID-19 in Wuhan, China: a retrospec-
tive cohort study. Lancet 395: 1054.
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